Recurrent Ectomesenchymoma
1 clinical trials · Condition
◉ Watch Recurrent Ectomesenchymoma
| Record | Firm | Date |
|---|---|---|
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774) | National Cancer Institute (NCI) | 2020-10-13 |
Track Recurrent Ectomesenchymoma automatically
Every clearance here is in the API, with alerts when new ones post.